血清TPS 与肝细胞肝癌临床病理特征的相关性探讨

 目的 探讨血清组织多肽特异性抗原(TPS)与肝细胞肝癌(HCC)临床病理特征的相关性。方法 采用酶联免疫吸附法，分别测定74例HCC患者、35例肝硬化患者、22例慢性肝炎患者和42例健康人体血清TPS和AFP水平。分析TPS与HCC临床病理特征的相关性，并与AFP比较。结果 HCC组TPS血清水平仅高于正常对照组(P<0．05)．与肝硬化及肝炎组比较无显著性差异(P>0．05)；TPS与DB、IB、ALT、AST、γ-GT、LDH以及肿瘤大小之间存在显著相关性(P<0．05)，但与肿瘤数目、门脉癌栓、肝外转移、临床分期及肿瘤分化程度均无显著相关性(P>0．05)；AFP与肿瘤大小、门脉癌栓及肿瘤分化程度之间存在显著相关性(P<0．05)。结论 血清TPS与HCC肿瘤侵袭性之间无显著相关性，但与肝功能受损程度相关性显著，因此必须谨慎对待肝病患者血清TPS的升高。     

河南省医用加速器多叶光栅小野输出因子验证测量方法研究

目的 调查放射治疗计划系统(TPS)计算的多叶光栅(MLC)小野输出因子,研究用0.015 cc电离室验证小野输出因子的测量方法。方法 在河南省选择8台可开展调强放射治疗的医用加速器,调查TPS计算的小野输出因子并与国际原子能机构(IAEA)推荐的出版值进行比。如果2 cm×2 cm照射野相对偏差超出IAEA要求的±3%,3 cm×3 cm、4 cm×4 cm、6 cm×6 cm照射野相对偏差超出IAEA要求的±2%,则用0.015 cc电离室和Unidos剂量仪进行测量验证。结果8台医用加速器的TPS计算小野输出因子与出版值比较,5台相对偏差符合IAEA要求,占调查总台数的62.5%,3台相对偏差超过IAEA要求,占调查总台数的37.5%。用针尖电离室测量验证,3台测量结果均符合IAEA要求。结论 河南省部分医用加速器TPS计算的MLC小野输出因子,需要现场实施小电离室测量修正,测量值作为制定放射治疗计划的依据。     

肾盂尿路上皮癌患者尿 NMP22、TPS、CYFRA21-1、CA19-9的检测与评估

目的探讨尿液核基质蛋白22(nuclear matrix protein 22,NMP22)、组织多肽特异性抗原(tissue polypeptide-specific antigen,TPS)、CYFRA21-1、糖链蛋白19-9(carbohydrate antigen 19-9,CA19-9)对肾盂尿路上皮癌的诊断价值.方法回顾性分析山西省肿瘤医院2010年1月至2015年12月检测的至少两种上述尿液肿瘤标志物的患者资料,共218人次,包括肾盂尿路上皮癌63例(A 组)、膀胱尿路上皮癌46例(B 组)、非尿路上皮肿瘤的泌尿系其他疾病62例(C 组)、A组行根治术后2年未复发47例(D 组),另有健康志愿者20例(E 组).比较各组尿 NMP22、TPS、CYFRA21-1、CA19-9表达水平,并绘制受试者工作特征(receiver operating characteristic,ROC)曲线,计算 ROC 曲线下面积.结果 A 组 NMP22水平高于 B 组,差异有统计学意义(P ＝0．001). A 组与 B 组的 TPS、CYFRA21-1、CA19-9水平差异无统计学意义(P ＞0．05).A 组和 B 组的 TPS、NMP22、CYFRA21-1、CA19-9水平均高于 C 组、D 组、E 组,差异有统计学意义(P ＜0?05).C 组、D组及 E 组的 NMP22、TPS、CYFRA21-1、CA19-9水平差异无统计学意义(P ＞0．05). A 组中NMP22、TPS、CYFRA21-1、CA19-9水平在不同病理分级、临床分期、肿瘤大小、是否肾积水等的差异无统计学意义(P ＞0．05).A 组 NMP22、TPS、CYFRA21-1、CA19-9的诊断准确率高于尿脱落细胞学检查,差异有统计学意义(P ＜0．05).四种肿瘤标志物的 ROC 曲线下面积为0．7~0．9,诊断效能中等,最高者为 NMP22与 CYFRA21-1的组合,为0．884.结论尿液 NMP22、TPS、CYFRA21-1、CA19-9对肾盂尿路上皮癌的诊断有帮助,诊断效能中等,但它们对肾盂癌肿瘤分期和病理分级的预测、术后监测、预后判断等方面的作用有待进一步研究.     

TPS、CEA和CYFRA21-1联合检测对非小细胞肺癌的诊断价值

目的：探讨组织多肽特异性抗原（TPS）、细胞角蛋白19片段（CYFRA21。1）和癌胚抗原（CEA）3项标志物联合检测对非小细胞肺癌的诊断价值。方法：应用酶联免疫吸附试验（ELISA）检测96例肺癌患者（肺癌组）和90例健康体检人员（对照组）的TPS、CYFRA21-1和CEA3项标志物。结果：肺癌组3项指标均明显高于对照组（P〈0．001）。TPS对肺癌诊断的敏感性为84．4％，特异性为88．9％；CYFRA21-1的敏感性为54．1％，特异性为93．3％；CEA的敏感性为45．8％．特异性为91．4％。3项联合则敏感性为100％。结论：TPS、CYFRA21-1和CEA对非小细胞肺癌的诊断有一定的价值，三者联合检测有明显的互补性．可明显提高非小细胞肺癌诊断的敏感性     

Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: A double-blind,randomized, multicenter,placebo-controlled clinical trial

Background

Rupatadine, a novel nonsedating second-generation H1-antihistamine with antiplatelet-activating factor activity, has been used in the treatment of allergic rhinitis and urticaria in European countries since 2003. However, its efficacy and safety in Japanese patients with chronic spontaneous urticaria (CSU) are unknown.

Leadless pacemaker: State of the art and incoming developments to broaden indications

Theleadless pacemaker (LLPM) therapy has been developed in recent years to overcome the transvenous lead and device pocket-related complications. The LLPMs now available are self-contained right ventricular pacemakers and are limited to single-chamber ventricular pacing modality. This literature review deals with the current status of LLPM technology and current areas of clinical applicability. The safety and efficacy outcomes published from randomized clinical trials and real world registries are analyzed and compared with historical conventional transvenous pacemaker data. Furthermore, new pacing modalities and future perspectives to broaden the clinical use and cover most of pacing indications are discussed. Due to the overall safe and effective profile in the short term and intermediate term, also in fragile patients, the LLPM use is constantly growing in daily clinical practice. Actually, it can be considered a landmark innovation, through which a new era of cardiac pacing has begun.     

Homocysteine Disulphides and Vascular Disease

Background: Tissue Polypeptide Specific antigen has recently been proposed as diagnostic marker of apoptosis in NonAlcoholic SteatoHepatitis.The aim of this study was to validate in patients suffering from NonAlcoholic SteatoHepatitis the clinical utility of this marker after different programs of weight reduction.Methods: Overweight/obese patients with visceral adiposity and liver histology compatible were assigned to a Calorically-Restricted diet (n = 22), a Calorically-Restricted diet plus EXercise (n = 19) or No Healthy Life Style (control group, n = 21) for six months. The presence of Body-Weight loss was assessed by a Body Mass Index decrease of at least three points. Serum ALanine aminoTransferase, HOmeostasis Model Assessment method value and Tissue Polypeptide Specific antigen concentrations were determined at time 0, after 3 and 6 months in both the Intervention groups and in the controls’ one.Results: In NonAlcoholic SteatoHepatitis patients who obtained Body-Weight reduction, a significant decrease of the serum Tissue Polypeptide Specific antigen values was showed with a clear linear trend across time, P = 0.0001.Decrement of Tissue Polypeptide Specific antigen concentrations best differentiated the Body-Weight loss from the body-weight maintenance in respect to Tissue Polypeptide Specific antigen and HOmeostasis Model Assessment method values.Conclusion: This study support the clinical utility of serum Tissue Polypeptide Specific antigen antigen levels in the follow-up of overweight/obese patients with NonAlcoholic SteatoHepatitis on weight reduction programs.     

CA15-3, CASA,MSA, and TPS as diagnostic serum markers in breast cancer

Summary This is the first comparison of the three mucin based tests CA15-3, CASA, and MSA, and the cytokeratin-related TPS assay in breast cancer. The mucin markers were superior to TPS in receiver-operator analysis, though no marker was of use in the diagnosis of malignancy due to low sensitivity. Using cutpoints that gave 95% specificity in benign disease (n = 83), corresponding sensitivities in pre-treatment breast cancer (n = 123: 13in situ, 54 stage I, 45 stage II, 4 stage III, 7 stage IV) were 17% (CA15-3), 16% (CASA), 13% (MSA), and 8% (TPS), with a strong relationship between marker levels and disease stage. These assays did not always detect the same patients, and the use of CA15-3 combined with CASA gave the highest sensitivity (23%), though this was not significantly better than the use of CA15-3 alone. Despite detecting similar antigens, these assays can show markedly different responses in some patients, indicating that one mucin-based test cannot be sub-stituted for another.